80% of pharma workers think Aduhelm's approval was a mistake, survey says

80% of pharma workers think Aduhelm's approval was a mistake, survey says

Source: 
Beckers Hospital Review
snippet: 

The majority of staffers and executives in the biotech and pharmaceutical industries disapprove of the FDA's approval of Biogen's Alzheimer's drug aducanumab, according to survey results released June 9 by Endpoints News.